Fusion Antibodies (LSE:FAB) ROCE % : -210.94% (As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Fusion Antibodies's annualized ROCE % for the quarter that ended in Sep. 2023 was -210.94%.

Fusion Antibodies ROCE % Historical Data

The historical data trend for Fusion Antibodies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies ROCE % Chart

Fusion Antibodies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

-24.74

-20.06

-25.21

-31.00

-116.77

Fusion Antibodies Semi-Annual Data
	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
ROCE %	Get a 7-Day Free Trial											-28.41	-33.81	-76.65	-159.01	-210.94

Fusion Antibodies ROCE % Calculation

Fusion Antibodies's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-2.855	/	( ( (4.915 - 1.208)	+	(2.062 - 0.879) )	/ 2 )
	=	-2.855	/	( (3.707	+	1.183)	/ 2 )
	=	-2.855	/	2.445
	=	-116.77 %

Fusion Antibodies's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Mar. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Mar. 2023 )		(Q: Sep. 2023 )
	=	-2.834	/	( ( (2.062 - 0.879)	+	(2.058 - 0.554) )	/ 2 )
	=	-2.834	/	( ( 1.183	+	1.504 )	/ 2 )
	=	-2.834	/	1.3435
	=	-210.94 %

(1) Note: The EBIT data used here is two times the semi-annual (Sep. 2023) EBIT data.

Fusion Antibodies (LSE:FAB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Fusion Antibodies ROCE % Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusion Antibodies (LSE:FAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL

Website

https://www.fusionantibodies.com

Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies (LSE:FAB) Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor • 10-21-2022